See more : Djerriwarrh Investments Limited (DJW.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Huons Co., Ltd. (243070.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Huons Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tecnisa S.A. (TCSA3.SA) Income Statement Analysis – Financial Results
- Genesis Growth Tech Acquisition Corp. (GGAA) Income Statement Analysis – Financial Results
- ASML Holding N.V. (ASML.WA) Income Statement Analysis – Financial Results
- Coinsilium Group Limited (CINGF) Income Statement Analysis – Financial Results
- Invictus MD Strategies Corp. (IVITF) Income Statement Analysis – Financial Results
Huons Co., Ltd. (243070.KQ)
About Huons Co., Ltd.
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, and other chemotherapeutic products; and injection products, such as anesthetic, antipyretic, analgesic, anti-inflammatory, skeletal muscle relaxant, antispasmodic, antihistamine, circulatory system, respiratory system, adrenocortical hormone, enzyme, mineral, solvent, calcium, hemostatic, antidote, antibiotic, metabolic, hyaluronic acid, well-being, anticoagulant, and other tissue cell system products. It also provides eye drop and bio products, as well as medical devices. The company was formerly known as Kwang Myung Pharm and changed its name to Huons Co., Ltd. in June 2003. Huons Co., Ltd. was founded in 1965 and is headquartered in Seongnam, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 552.01B | 492.39B | 436.91B | 406.68B | 365.02B | 328.60B | 284.84B | 168.97B | 182.34B |
| Cost of Revenue | 266.07B | 227.87B | 192.72B | 189.11B | 166.73B | 147.87B | 129.10B | 79.78B | 87.90B |
| Gross Profit | 285.94B | 264.52B | 244.19B | 217.56B | 198.29B | 180.72B | 155.73B | 89.19B | 94.44B |
| Gross Profit Ratio | 51.80% | 53.72% | 55.89% | 53.50% | 54.32% | 55.00% | 54.67% | 52.79% | 51.79% |
| Research & Development | 32.88B | 37.87B | 30.01B | 26.54B | 25.29B | 20.69B | 19.86B | 14.20B | 0.00 |
| General & Administrative | 10.53B | 9.49B | 9.15B | 8.62B | 1.74B | 1.80B | 1.76B | 1.58B | 0.00 |
| Selling & Marketing | 147.38B | 136.57B | 122.70B | 96.42B | 86.61B | 80.41B | 68.36B | 52.09B | 0.00 |
| SG&A | 193.26B | 186.59B | 168.96B | 136.10B | 124.12B | 114.30B | 99.26B | 53.33B | 64.34B |
| Other Expenses | 0.00 | -588.55M | -775.80M | -793.36M | -485.43M | -448.18M | -393.83M | -135.66M | 0.00 |
| Operating Expenses | 226.15B | 225.05B | 199.75B | 163.44B | 149.90B | 135.44B | 119.52B | 67.66B | 64.34B |
| Cost & Expenses | 492.21B | 452.92B | 392.47B | 352.55B | 316.63B | 283.31B | 248.62B | 147.44B | 152.24B |
| Interest Income | 2.11B | 1.98B | 764.89M | 711.04M | 643.68M | 465.45M | 682.45M | 784.34M | 810.32M |
| Interest Expense | 2.50B | 3.16B | 2.69B | 1.80B | 1.13B | 958.24M | 1.08B | 590.18M | 2.09B |
| Depreciation & Amortization | 18.23B | 16.73B | 12.85B | 11.83B | 9.86B | 6.42B | 5.26B | 4.18B | -2.75B |
| EBITDA | 83.84B | 57.60B | 58.13B | 65.95B | 58.25B | 51.71B | 41.47B | 25.12B | 31.34B |
| EBITDA Ratio | 15.19% | 11.41% | 13.11% | 16.22% | 15.96% | 15.74% | 14.56% | 15.22% | 15.00% |
| Operating Income | 59.79B | 39.47B | 44.44B | 54.12B | 48.39B | 45.28B | 36.22B | 21.53B | 30.10B |
| Operating Income Ratio | 10.83% | 8.02% | 10.17% | 13.31% | 13.26% | 13.78% | 12.72% | 12.74% | 16.51% |
| Total Other Income/Expenses | 3.32B | -609.50M | -4.42B | 14.33B | -561.60M | 9.40B | 8.08B | -1.18B | -845.55M |
| Income Before Tax | 63.11B | 40.18B | 43.69B | 70.69B | 49.82B | 55.97B | 44.81B | 20.35B | 29.25B |
| Income Before Tax Ratio | 11.43% | 8.16% | 10.00% | 17.38% | 13.65% | 17.03% | 15.73% | 12.04% | 16.04% |
| Income Tax Expense | 12.72B | 17.65B | 10.28B | 14.96B | 10.42B | 11.37B | 10.05B | 5.04B | 4.76B |
| Net Income | 50.47B | 22.44B | 30.75B | 55.58B | 38.21B | 45.23B | 35.07B | 15.33B | 20.93B |
| Net Income Ratio | 9.14% | 4.56% | 7.04% | 13.67% | 10.47% | 13.77% | 12.31% | 9.07% | 11.48% |
| EPS | 4.26K | 1.90K | 2.86K | 5.13K | 3.20K | 3.79K | 2.22K | 1.35K | 905.18 |
| EPS Diluted | 4.11K | 1.90K | 2.80K | 5.10K | 3.20K | 3.79K | 2.22K | 1.35K | 905.18 |
| Weighted Avg Shares Out | 11.85M | 11.83M | 10.76M | 10.83M | 11.94M | 11.94M | 15.77M | 11.39M | 23.13M |
| Weighted Avg Shares Out (Dil) | 12.27M | 11.83M | 11.78M | 10.95M | 11.94M | 11.94M | 15.77M | 11.39M | 23.13M |
Source: https://incomestatements.info
Category: Stock Reports